Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII ...

A factor VIII assay tests for a protein involved in blood clotting. If you produce less of this protein, it may indicate a bleeding disorder. Some people may also have high levels of this ...

这项研究表明，抗 CD19 CAR - T 细胞疗法能够使难治性 AHA 患者诱导缓解，为这一疾病的治疗提供了一种有前景、安全且可能具有成本效益的治疗选择。不过，研究人员也指出，AHA 患者的 CAR - T 细胞扩增动力学与其他自身免疫性疾病存在差异，推测可能与检测到优势 B 细胞克隆的时间有关，但这还需要进一步研究来证实。

a There were no statistically significant differences between groups in gender, race and ethnicity, blood product transfusion, total parenteral nutrition, platelet count, prothrombin time ...

Image Source: Zacks Investment Research A rare genetic blood disorder, hemophilia is caused by a missing clotting protein Factor VIII (FVIII) in hemophilia A, which prevents normal blood clotting.

Citing that there is unmet medical need in the country for the proposed indication, the Subject Expert Committee (SEC) ...